IL17A and neoplasm: • Low neutrophil surface expression necessitating priming:→ In vitro (GM‐CSF/IL‐17/LPS* or TNF†)→ In vivo (post‐extravasation, TNF‐dependent†)• Expressed on tumour‐associated neutrophil N1 type*